Traitement prophylactique de la maladie thromboembolique veineuse en soins palliatifs

the absence of recommendations based on validated clinical trials evaluating the efficacy and safety of thrombembolism prophylactic treatment in palliative care patients lead to uncertain decisions for clinicians. Added to an objective evaluation of thrombotic and hemorrhagic risks factors, the wish of patient to receive or not active care is probably the most important element to consider.